Clinical trial · no report yet · Phase 3
TROPION-Lung08
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT05215340 ↗
- Active not recruiting
- Daiichi Sankyo
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| Podcasts | 6 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan; Pembrolizumab
- Arms
- Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd) · Experimental
- Pembrolizumb · Active comparator
- Enrollment
- 740
- Primary outcomes
- Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab
- Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab
- Sponsor
- Daiichi Sankyo with AstraZeneca, Merck Sharp & Dohme LLC
- Start
- Mar 4, 2022
- Primary completion
- Mar 4, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05215340 · updated Sep 24, 2026
Publications
linked from the registry- Levy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, Zhou C, Rawat S, Xie J, Basak P, Xu L, Sands J. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023 Jul;19(21):1461-1472. doi: 10.2217/fon-2023-0230. Epub 2023 May 30. PubMed 37249038